However, since our cohort comprised seven secondary GBM and our goal was to assess the impact of TGF-β levels on survival of relapsing tumor patients, post-reoperation survival (PRS) was used as surrogate instead of OS. This evidence concerns the gene TGFB1 and glioblastoma.